Clinical Research Directory
Browse clinical research sites, groups, and studies.
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
Sponsor: Mayo Clinic
Summary
Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (\>50%) risk of future life-threatening recurrences and death.
Official title: Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer Who Have Residual Disease After Neoadjuvant Systemic Therapy
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
999
Start Date
2021-01-13
Completion Date
2042-01-15
Last Updated
2026-03-03
Healthy Volunteers
No
Conditions
Interventions
chemotherapy or endocrine therapy for breast cancer
Collect blood and leftover surgical tissue from patients with breast cancer remaining after chemotherapy or endocrine therapy is completed.
Locations (1)
Mayo Clinic
Rochester, Minnesota, United States